{"id":391701,"date":"2014-03-31T00:00:00","date_gmt":"2014-03-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0314-biopharma-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-relapsed-refractory-decision-base-us\/"},"modified":"2026-04-15T23:28:25","modified_gmt":"2026-04-15T23:28:25","slug":"dbason0314-biopharma-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-relapsed-refractory-decision-base-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbason0314-biopharma-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-relapsed-refractory-decision-base-us\/","title":{"rendered":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (Relapsed\/Refractory) | Decision Base | US | 2014"},"content":{"rendered":"<p><em>As the Relapsed\/Refractory Treatment Setting for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma Becomes More Crowded, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers?<\/em><\/p>\n<p>The introduction of the anti-CD20 monoclonal antibody (MAb) rituximab (Roche\/Genentech\/Chugai Seiyaku\/Zenyaku Kogyo\u2019s Rituxan\/MabThera) profoundly revolutionized the treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). Although the MAbs alemtuzumab (Sanofi\/Genzyme\u2019s Campath\/MabCampath) and ofatumumab (GlaxoSmithKline\/Genmab\u2019s Arzerra) have expanded treatment options for relapsed\/refractory (R\/R) CLL\/SLL, this heterogenic patient population remains difficult to treat. The February 2014 approval of ibrutinib (Johnson &#038; Johnson\/Janssen\/Pharmacyclics\u2019 Imbruvica) represents a significant milestone in the treatment of R\/R CLL and will serve to increase competition in the market. Nevertheless, significant clinical and commercial opportunity remains for therapies that can provide survival benefits greater than those of current standards of care.<\/p>\n","protected":false},"template":"","class_list":["post-391701","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391701\/revisions"}],"predecessor-version":[{"id":577042,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391701\/revisions\/577042"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}